MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in the 2026...
$21,894K
Proceeds from issuance of
pre-funded warrants in the...
$15,372K
Proceeds from issuance of
common stock under the...
$39K
Proceeds from exercise of
stock options
$24K
Maturities of investments
$10,993K
Net cash provided by
financing activities
$37,329K
Net cash provided by
investing activities
$8,290K
Canceled cashflow
$2,703K
Net increase
(decrease) in cash and cash...
$33,546K
Canceled cashflow
$12,073K
Stock-based compensation
expense
$1,460K
Purchases of investments
$2,703K
Net cash used in
operating activities
-$12,073K
Canceled cashflow
$1,460K
Net loss
-$10,028K
Accrued compensation
-$1,805K
Other current
liabilities
-$662K
Accounts payable
-$405K
Accrued liabilities
-$285K
Prepaid expenses and
other assets
$267K
Net accretion of
discount on investments
$81K
Back
Back
Cash Flow
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)
source: myfinsight.com